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Hereditary non-polyposis colorectal cancer (HNPCC -Lynch syndrome) is an autosomal dominant disorder characterized by the development of colorectal cancer at an early age, a preponderance of tumors in the proximal colon, and an excess of multiple primary cancers [1] . In families with HNPCC extra-colonic tumors such as cancers of the endometrium, small bowel, hepatobiliary tract, urinary tract, ovary, stomach or brain occur with increased frequency [2] [3] [4] [5] . Although genes related to the predisposition of HNPCC have already been cloned (hMLH1, hMSH2, hPMS2, hMSH6, and hMLH3), the detailed analysis of pedigree and clinical data remains crucial for the diagnosis of this disorder when determining a person's qualification for surveillance and gene testing [6] [7] [8] [9] [10] . According to the International Collaborative Group on HNPCC (ICG-HNPCC) the disease can be diagnosed when the Amsterdam criteria are matched, these being: 1) three or more relatives with histologically verified colorectal cancer (CRC), one of whom is first degree to the other two; 2) colorectal cancer affecting at least two generations, and 3) one or more colorectal cancer cases diagnosed under the age of 50 and 4) familial adenomatous polyposis is excluded [11] .
The ICG-HNPCC criteria were revised in 1999 [12] . The term "colorectal cancer" was changed to "HNPCC-associated cancer". HNPCC-associated cancers include colorectal cancer and cancers of the endometrium, small bowel, renal pelvis or ureter.
The ICG-HNPCC criteria for the diagnosis of HNPCC are very restrictive and they do not allow for the inclusion of a large number of "suspected HNPCC" cases -that is families that do not fulfill the Amsterdam criteria, but present with several pedigree and clinical features characteristic of HNPCC. In several different series of families suspected of HNPCC but not fulfilling the diagnostic criteria, germline mutations were found in 8-60% of kindreds [13] [14] [15] [16] [17] . Therefore a subgroup of members of the ICG-HNPCC has been working on a pedigree/clinical diagnostic protocol for suspected cases of HNPCC. Recently, such criteria (shown in Table 1 ) were revised by Park et al. [16] . Park et al. (1999) agree that further refinements of the criteria are needed to improve the identification of HNPCC families. In our experience the most important limitations in the application of pedigree/clinical data in the diagnosis of HNPCC are problems with the availability of medical documentation of patients' relatives and the small size of contemporary families.
Therefore, in the study reported here we aimed to identify criteria based on nuclear pedigree and clinical analyses whilst maintaining the diagnosis of HNPCC with a high degree of sensitivity and specificity. Presence of synchronous or metachronous colorectal tumors in the patient, one of which occurred under the age of 40 years.
Endometrial, urinary tract, or small-intestinal cancer in the patient or a first degree relative (one aged <50 years).
At least two first degree relatives (one aged <50 years) with other extra-colonic cancers (stomach, hepatobiliary system, ovary, or brain).
(18 CRCs), Leiden, Holland (23 CRCs) and Szczecin, Poland (47 CRCs). For 43 of these patients, information about the occurrence of constitutional MSH2 or MLH1 mutations were obtained. Patients for analysis from a given family were selected only from the youngest generation of individuals affected by cancers ( Fig. 1 ). This selection system was chosen in order to avoid bias related to improvements in diagnostic procedures (colonoscopies were less frequently performed 10 years earlier) and potential anticipation of age at diagnosis in recent generations.
2) Consecutive CRCs -this group comprised 629 (78.0%) of 806 individuals with recently diagnosed CRC in 1991-1997 in the city of Szczecin (ca. 400,000 of inhabitants), Poland.
Nuclear pedigrees in both groups were compared for the occurrence of clinical features that have been shown to be associated with HNPCC. The analyzed features are summarized in Table 2 .
Univariate statistical analyses -X 2 , odds ratio (OR), confidence interval (CI) -95%, sensitivity and specificity were performed using SAS program and LOGIT method.
P Pa ar rt t I II I
52 consecutive CRC cases from HCC in Szczecin, matching F1, (F3 and/or F5) but not Amsterdam II criteria were studied for the occurrence of germline hMSH2/hMLH1 constitutional mutations using "exon by exon" sequencing. 
R Re es su ul lt ts s
The results of the genomic DNA sequencing analyses are summarized in Table 3 . All of the defined features (F1-F5) were confirmed to be very strongly associated to HNPCC with an OR of 15 to 155 depending on which feature was chosen for the clinical and or pedigree diagnosis. The only exception was feature F2, where it was impossible to show that the occurrences of cancers of the stomach, hepatobiliary tract, ovary, pancreas or gliomas among first degree relatives of CRC patients are characteristic for HNPCC (OR -0.42). The strongest association to HNPCC was the occurrence of one first degree relative with one of either colon, rectum, endometrium, small bowel or urinary tract cancer OR 155.2. However, aggregation of at least two first degree relatives affected by an HNPCC associated cancer has been shown not to be characteristic of HNPCC in families who do not have disease diagnosed under the age of 50 years (OR -0.23).
In contrast, combining features F1 and (F3 and/or F5) -a situation where an HNPCC closely associated cancer is found in first degree relatives of CRC patients and one of these cancers is diagnosed under age of 50, appeared to be strongly associated with HNPCC (OR -161). The occurrence of sporadic cancer diagnosed under the age of 40 years (combinations F4 without F1 and without F2) has been found not to be characteristic of HNPCC (OR -0.17). 
D Di is sc cu us ss si io on n
The results of our studies strongly suggest that it is possible to diagnose HNPCC with a high degree of accuracy on the basis of nuclear pedigree data and clinical features alone. One simple criterion -the occurrence of two or more HNPCC closely associated cancers (cancer of the colon, rectum, endometrium, small bowel and urinary tract) in first degree relatives of patients with CRC with at least one of the cancers is diagnosed under the age of 50 -can be used to identify HNPCC with an OR -161. Unexpectedly, we found that the diagnosis of suspected HNPCC is not possible on the basis of nuclear pedigree analysis alone if patients with CRC are diagnosed under the age of 40 and without a first degree relative affected by an HNPCC associated malignancy.
The analyses performed in this report are an alternative approach for the diagnosis of HNPCC on clinical criteria based on the statistical assessment of the frequency of specifically analyzed features between the study population and control groups of patients T Ta ab bl le e 4 4. . S St ta at ti is st ti ic ca al l a an na al ly ys si is s o of f n nu uc cl le ea ar r p pe ed di ig gr re ee e c cl li in ni ic ca al l f fe ea at tu ur re es s o of f C CR RC C p pa at ti ie en nt ts s w wi it th h i id de en nt ti if fi ie ed d m mu ut ta at ti io on ns s with CRC. Previous studies by Percesepe et al. were performed using a different methodology [17] . For the assessment of independent significance of each feature they applied multivariate analysis. In order to exclude potential errors of their analyses we decided to apply in our approach the more direct verification of early onset of CRC as an independent HNPCC predictor by excluding from the analysis the "age at diagnosis" in cases that matched other criteria.
The methodologies applied in the current study were undertaken because results of a molecular search for MSH2/MLH1 mutations were simultaneously performed in our center -in none of the 10 sporadic CRCs diagnosed under the age of 40, were we able to detect molecular genetic changes. Thus, together with results of nuclear pedigree studies presented herein, we have verified the utility of nuclear pedigree criteria for the identification of HNPCC families.
Park et al. reported the occurrence of MSH2/MLH1 mutations among 6% (3 of 50 cases) of sporadic early onset CRCs [16] . The proportion of mutations in HNPCC genes in unselected CRCs is between 2-3%. The results reported by Park et al. suggest that in patients with sporadic early onset CRC the probability of finding DNA mismatch repair gene mutations is more than twice as high. In relation to our results, Park's findings can be explained by a bias brought about by the small number of cases used in their study.
The results of our study strongly indicate that caution must be taken in defining the criteria of diagnosis for genetic disorders and the usefulness of the methodological approach developed in this report. Wherever possible, analyses for independent significance of the studied features should be verified by the construction of subgroups that define the potential criteria for selection.
We believe that the criteria defined in this report can be further improved. There are several other pedigree/clinical features of potential diagnostic significance such as, right-sided tumor localization, tumor multiplicity or mucinous histology of CRC [17] .
In order to develop more accurate criteria it is crucial to register a much larger number of HNPCC cases displaying a series of specific features. In our experience, nuclear pedigree criteria of suspected HNPCC defined in this paper are of enormous practical significance for the identification of HNPCC families subsequent to DNA testing and surveillance.
